This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (January 2022)
Catalent, Inc.
Company type
Public
Traded as
NYSE: CTLT
S&P 500 component
Industry
Pharmaceuticals
Predecessor
Cardinal Health PTS
Founded
2007; 17 years ago (2007)
Headquarters
Somerset, New Jersey, U.S.
Number of locations
52 (2023)
Key people
Alessandro Maselli (President, CEO & Director), Matti Masanovich (CFO)
Services
Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
Revenue
US$4.26 billion (2023)
Operating income
US$−163 million (2023)
Net income
US$−256 million (2023)
Total assets
US$10.8 billion (2023)
Total equity
US$4.61 billion (2023)
Number of employees
17,800 (2023)
Website
catalent.com
Footnotes / references Financials as of June 30, 2023[update].[1]
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[2] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[3]
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]
In 2014, Catalent became a public company, listed on the New York Stock Exchange.
^"2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 8 December 2023.
^"Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency". BioSpace. Archived from the original on 1 November 2020. Retrieved 8 November 2020.
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies...
Baden Springs Hotel and the French Lick Springs Hotel. In September 2017, Catalent purchased Cook Pharmica for $950 million. In February 2022, Cook Medical...
starch and carrageenan. Catalent Pharma Solutions is the current owner of the RPScherer technology. Capsule Paintballs Catalent Softgel website v t e...
In February 2024, parent company Novo Holdings A/S agreed to acquire Catalent for $16.5 billion. On completion, Novo Nordisk said it would acquire three...
technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. The technology's first commercial application...
2023. It was developed by Sarepta Therapeutics and is manufactured by Catalent. Delandistrogene moxeparvovec is indicated for the treatment of ambulatory...
1998. and subsequently named Catalent Pharma Solutions. "Honoring An Original". Retrieved 2018-10-18. Cardinal.com The Catalent Pharma Solution homepage The...
and fuel cards), and Allstar (fuel card); also nearby are Cartus Europe, Catalent Pharma Solutions UK and MAN Truck & Bus UK (with Neoplan and ERF); further...
peripheral artery disease delandistrogene moxeparvovec Elevidys In vivo Catalent Duchenne muscular dystrophy 22 June 2023 No elivaldogene autotemcel Skysona...
pharmaceutical companies such as Canada's Patheon and the United States-based Catalent Pharma Solutions and French medical supplies manufacturer Vygon (UK) have...
national and international corporations such as Intel, Motorola, Patheon, Catalent (formerly known as Cardinal Health), Becton-Dickinson, WHSmith, Early Learning...
addition of mannitol to increase binding and decrease dissolution time). Catalent Pharma Solutions (formerly Scherer DDS) in the U.K., Cima Labs and Fuisz...
Moore & Co. Bradco Supply Burlington Coat Factory Campbell Soup Company Catalent Ce De Candy, Inc. Celgene Century 21 Real Estate The Children's Place Chubb...
Post. Constantino, Annika Kim (2024-02-05). "Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply". CNBC. "Pfizer Ends $160B Acquisition...
MacDonald G (3 December 2015). "GSK Japan delays alopecia drug launch after Catalent manufacturing halt". Archived from the original on 1 October 2016. Retrieved...
Global Information
US$4.26 billion (2023)
US$10.8 billion (2023)